MCP-1/IL-6 in vitro monocyte secretion upon coculture with autologous fragment spheroids was studied in relation to patient 5-and 10-year overall survival rates in head and neck squamous cell carcinoma (HNSCC) patients (n = 65) diagnosed between 1998 and 2005, nine of whom had an human papilloma virus (HPV) tumour infection. The spheroids were harvested from malignant or benign tissue during primary surgery. Two weeks following surgery, freshly isolated autologous monocytes and benign or malignant spheroids were cocultured 24 h in vitro. The IL-6 secretion was expressed as a fraction of the lipopolysaccharide (LPS) response from the same batch of monocytes. HPV status was obtained by employing PCR analyses of primary diagnostic blocks. IL-6/MCP-1 response levels were not found to be dependent on HPV infection status. MCP-1 secretion did not predict prognosis, nor did in vitro IL-6 monocyte background or LPS-stimulated IL-6 secretion. At 5-year observation, dichotomized IL-6 levels following monocyte coculture, with both malignant and benign spheroids, showed a strong trend towards predicting survival, that is a low monocyte malignant coculture response showed a survival of 31 AE 17 versus 58 AE 17% with a high such response (P = 0.057). When studying monocyte IL-6 coculture responses evaluating benign and malignant spheroid results statistically together, a prediction of survival up to 10 years was found (hazard ratio = 0.48; confidence interval = 0.24-0.96; P < 0.05) with double low IL-6 responses. This survival prediction was also present after an adjustment for HPV tumour infection status. In conclusion, monocyte IL-6 in vitro secretion in cocultures with autologous spheroids/serum from HNSCCs predicted 5-and 10-year survivals, both with and without tumour HPV tumour adjustment.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is a disease group with a variable incidence throughout the world [1] . This suggests that these diseases are caused by environmental factors [2] such as smoking, but also related to infectious agents [3] , mediated in part through inflammation [4, 5] . A growing knowledge about the human papilloma virus (HPV) as a pathogen of the current oropharynx SCC epidemic [6] [7] [8] also supports the addressing of the role of inflammation related to HNSCC.
Several authors have shown that the functional status of the immune system is related to the prognosis of HNSCC [9] [10] [11] . Furthermore, the immune system participates in the eradication of HPV-positive (+) tumour cells during radiotherapy [12] and also presumably so among HPVnegative (À) patients. The roles of the immune system in cases of HNSCC beyond these findings are not well studied. Moreover, the potentially different roles of the immune system in HPVÀ versus HPV+ HNSCC patients have also not been extensively investigated.
Immune therapy for cancer patients has been considered to be one of the most promising areas of new cancer therapy for carcinomas [13] [14] [15] , including upper [16, 17] aerodigestive SCC. a-PD-1 therapy to melanoma patients is one prime example [18] of a new immune therapy, which has also been suggested regarding HNSCC [16, 17] . The PD-1 epitope is primarily located on T lymphocytes, but may also be found on monocytes and macrophages [19] . Such a therapy may also affect mononuclear phagocyte (MNP) function, thus adding to the interest regarding the HNSCC-MNP axis.
We have previously shown that HPV+ compared to HPV-HNSCC patients had lower in vitro monocyte lipopolysaccharide (LPS)-stimulated interleukin (IL)-6 responses. A high LPS-stimulated in vitro monocyte IL-6 response furthermore predicted decreased survival, to some extent independent of HPV infection status [10] . A high percentage of CD71-positive T lymphocytes also predicted an impaired prognosis. In a multivariate analysis using these data, IL-6 secretion and the percentage of CD71-positive T lymphocytes both uniquely predicted a survival independent of HPV infection status. In particular, patients with evidence of a high functioning in both the adaptive and natural immune systems had a serious prognosis. Similar results were obtained with monocyte chemo-attractant protein (MCP)-1 secretion and the percentage of CD69-positive lymphocyte analyses [11] . As stimulated by LPS, HNSCC monocyte function is therefore known to predict prognosis, and in the current study we aim to investigate monocyte function upon cancerassociated stimuli.
We have a long-standing line of basic science experiments studying monocytes stimulated by HNSCC tumourderived spheroids or benign squamous tissue control spheroids in vitro under autologous conditions [20] . Such monocytes secrete IL-6 and MCP-1 [21] . The spheroids alone also secrete these cytokines, although in minor amounts [22] . Remarkably, we have generally shown that the benign and malignant coculture responses behave in the same manner [23] . This demonstrates important matters about the mechanisms of these responses. Therefore, both the benign and malignant coculture responses have been included in the present prognostic studies. We have previously published that levels of IL-6 sampled from this series of in vitro cocultures with benign spheroids predicted recurrence [24] . The present paper reports on long-term survival, that is at 5 and 10 years. In addition, we have studied the importance of HPV infection on HNSCC patients regarding these predictions.
The MNP system is a central directing element in the immune system and serves this role through four basic 'SHIP' functions in vivo: sample, heal, inhibit, and present antigen [25] . Mononuclear phagocytes secrete pro-inflammatory cytokines like IL-6 [26] , as well as chemokines like MCP-1 [27] . IL-6 is predominantly a pro-inflammatory cytokine, but may also stimulate cancer cell growth [25] . MCP-1 was originally determined to recruit monocytes [27] , and serum levels predict prognosis in HNSCC [28] . Evidence therefore suggests that MNPs can promote apoptosis of tumour cells [29] , as well as secrete tumourstimulating cytokines [30] . What the net MNP function is concerning tumour biology in vivo seems to be complex and needs to be more closely investigated.
IL-6 levels are associated with a prognosis in various cancer diseases [15] , HNSCC included [10, 28, 31, 32] . In general, several cytokines shown to be of prognostic value are abundantly secreted by activated MNPs [33] . Therefore, to study MNP cytokine secretion following directly tumour-derived stimuli should be highly relevant. We have determined 5-and 10-year overall survivals, as well as whether the tumours were HPV infected, and then report the outcome based on monocyte coculture stimulated IL-6 secretion. Indeed, the prognosis was dependent on the IL-6 secretion level.
Materials and methods
Patients. Patients treated with primary surgery for HNSCCs were included in the study, while primary tumour sites and TNM stages were as described earlier [24] . All patients were M0 at inclusion. The Regional Committee for Medical Ethics in the Health West Region, Bergen, Norway, has approved the study, and before participation in the study, each patient gave their written consent. The study was comprised of 65 consecutively included patients treated between 1998 and 2005 at the Department of Otolaryngology and Head and Neck Surgery, Haukeland University Hospital, Bergen, Norway. Overall survival was determined at 5 and 10 years following inclusion to the study. Sixty-five patients with results from malignant coculture and 60 patients with results from a benign coculture were included. Of these, 30 and 22 patients were alive following 5 or 10 years of observation, respectively.
Spheroid generation. As previously described, free floating spheroids were established by the use of an organ culture model [21] . At surgery, biopsies were obtained from both tumour and benign mucosa distally from the frozen section biopsies. Macroscopically, vital tissue was randomly chopped from malignant tissue, whereas benign tissue was harvested from the epithelial part of the mucosa biopsies. Cubes, with a size of 0.5-1.0 mm, were transferred to agar-coated tissue culture flasks (Nunc A/S, Roskilde, Denmark). Moreover, Dulbecco's MEM was used for fragment spheroid cultures, supplemented with 15% heat-inactivated foetal bovine serum (FBS; Sigma, St. Louis, MO, USA), penicillin (100 IU/ml), streptomycin (100 lg/ml), amphotericin (2.5 lg/ml), L-glutamine (2 mM) and a non-essential amino acid mixture (1%; all from BioWhittaker, Walkersville, MD, USA). The cultures were maintained at 37°C in 5% CO 2 and 95% air with 100% relative humidity. Fragments which had rounded to spheroid-like structures after 10-14 days in vitro were selected for experiments, with Monocyte and serum preparation. About 2 weeks postoperatively, peripheral blood mononuclear cells (PBMCs) drawn at 7.30 a.m. were separated by gradient centrifugation with Lymphoprep© (Nycomed, Oslo, Norway) as the density gradient medium, as previously described [21] . The PBMC yield of 8.5 ml of blood was allocated to all wells in a 24-well plate (Nunc) with RPMI-1640, supplemented with penicillin (100 IU/ml), streptomycin (100 lg/ml), amphotericin (2.5 lg/ml), L-glutamine (2 mM) and 20% autologous serum to a total volume of 0.5 ml/well. After 40 min of pre-incubation, the monocytes were purified by washing and then cultured in RPMI/ 20% autologous serum, 0.5 ml/well. Generally speaking, more than 95% of the cells were positive for non-specific esterase stain and viability exceeded 95%, as tested by the Trypan Blue stain.
Coculture. Approximately 14 days post-operatively, malignant or benign fragment spheroids were washed and transferred to freshly isolated monocyte cultures in 24 9 16 mm well plates (Nunc) with 0.5 ml RPMI/20% autologous serum per well. Four to six spheroids per well were employed. Monocytes cultured in wells with the indicated medium, both with and without the addition of 1 lg/ml LPS from Escherichia coli (Sigma) serving as controls. Due to systematic variations among kits as to the reported IL-6 concentrations, the IL-6 secretion rate was calculated as a relative response (RR) according to the following formula:
RR ¼ pg/ml co-culture secretion -pg/ml background secretion pg/ml LPS-stimulated secretion -pg/ml background secretion IL-6 and MCP-1 ELISA. The contents of IL-6 and MCP-1 were determined by ELISA using MCP-1/IL-6 capture and detection antibody pairs, compared to recombinant human (r-hu) MCP-1/IL-6 as standards (R&D Systems Europe Ltd, Abingdon, UK). All procedures were performed according to the specifications of the manufacturer. In short, 96-well microtiter plates (Costar Corning, Sigma) were coated overnight at room temperature (RT) with monoclonal mouse anti-human MCP-1 or IL-6 capture antibodies, respectively. After blocking, diluted samples or r-hu respective standards were added and incubated for 2 h at RT followed by the addition of biotinylated polyclonal goat anti-human MCP-1 or IL-6, respectively. The plates were then incubated for 20 min at RT with streptavidin-conjugated horseradish peroxidase, and tetramethylbenzidine (TMB; Sigma) and H 2 O 2 were used as substrates. Absorbency values were measured at 450 nm using Softmax Pro version 4.0 on an Emax precision microtiter plate reader (Molecular Devices, Sunnyvale, CA, USA). The lower detection level was 9.4 pg/ml for IL-6 and 15.6 pg/ml for MCP-1. DNA isolation. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) specimens. These were tissues from primary HN tumours in diagnostic or surgical samples, or from lymph node metastatic lesions. Three 10-lm-thick FFPE sections were deparaffinized in xylene and ethanol and digested overnight in ATL buffer and Proteinase K (Qiagen GmbH, Hilden, Germany) at 56°C. DNA was extracted using the EZNA tissue DNA kit (Omega Bio-Tek, Norcross, GA, USA). The DNA concentration was then measured on a NanoDrop spectrophotometer (NanoDrop, Minneapolis, MN, USA). HPV-negative DNA (control) samples were isolated from blocks provided from human large bowel FFPE tissue samples. For every fourth sectioned ENT specimen, a control (HPV-negative) block was sectioned as internal negative controls to test for the potential risk of HPV contamination in the procedure. All interspersed negative sample controls had to be negative to accept any positive HPV PCR results. Furthermore, all tumour samples were reviewed by an expert in pathology (OKV), and representative FFPE tissue samples were selected for HPV DNA analysis.
HPV DNA detection. For the detection of HPV DNA standard, Gp5+/Gp6+ primers were used [17] . The PCR mix consisted of Multiplex Mastermix PCR kit (Qiagen GmbH), 2 ll of primer mix and 2 ll of DNA run in a volume of 20 ll. The samples were inactivated by heating (95°C) for 15 min and then running 38 cycles at 94°C for 45 s, 43°C for 90 s, 72°C for 90 s and finally 72°C for 10 min. As positive PCR controls, known HPV DNA-positive samples were included, and as negative PCR controls, the substrate DNA was omitted.
The PCR products were separated and visualized on a 3% agarose gel. Only samples with distinct PCR bands were considered positive for HPV and further processed for HPV subtype identity by DNA sequencing. First, the PCR products were purified by incubation with ExoStar (GE Healthcare, Buckinghamshire, Great Britain) at 37°C for 15 min, followed by enzyme inactivation at 80°C for 15 min. The purified PCR products were then prepared for sequencing using the same primers as for the initial PCR in combination with BigDyeâ Terminator v1.1 Cycle Sequencing kit (Life Technologies, Foster City, CA, USA). Before being analysed on a 3130XL Genetic Analyzer (Life Technologies), the products of the sequencing reaction were purified using BigDyeâ Xterminator kit (Life Technologies). The HPV DNA sequences were identified using the NCBI BLAST database. A more than 98% homology was regularly observed with NCBI BLAST.
HPV status of included patients. Ten HNSCC patients from the original total cohort were positive for HPV DNA, all with tumours originating from the oropharynx. These tumours originated from the tonsils (n = 7), the basis of the tongue (n = 2) and the lateral wall of the oropharynx (n = 1); however, we lacked the actual diagnostic biopsies from three HNSCC patients. None of these patients had tumours originating from the oropharynx, so we therefore designated them as HPV-negative patients.
Statistics. The statistical program package SPSS (version 22; SPSS, Chicago, IL, USA) was used.
Results

HPV tumour infection and survival
The present cohort included nine HPV+ patients. The overall survival of the HPV+ versus HPV-patients was determined at 5 and 10 years of observation. At 5 years, none of the HPV+ patients were dead (100% survival), whereas the survival was 36 AE 10% in the HPV-group (P < 0.001). At the 10-year observation, one of the HPV+ patients had died (92 AE 16% survival). The survival of the HPV-patient group was 24 AE 8% (P < 0.001) at this time point (Fig. 2) .
Monocyte coculture responses dependent on HPV tumour status of the patient
The monocyte coculture secretion levels did not depend on the HPV status of the tumours (Table 1 ). Aarstad et al.  .............................................................................................................................................................. 
....
Covariation from monocyte 24-h in vitro IL-6 or MCP-1 secretion employing malignant or benign spheroids A significant correlation was found between monocyte IL-6 secretions following stimulation with malignant or benign spheroids (Table 2) . Similarly, MCP-1 secretion was found to correlate when stimulated with malignant or benign spheroids in vitro. No significant correlations were determined between IL-6 and MCP-1 secretion rate.
Prognosis according to clinical inflammation parameters
The obtained albumin levels predicted survival at the 10-year observation, that is 48 AE 9% with high value versus 21 AE 15% with low value (P < 0.05). Furthermore, a high haemoglobin value at diagnosis, when analysed dichotomized, predicted an improved survival at 5-year (58 AE 19 versus 31 AE 17%; P < 0.05) and 10-year (48 AE 14 versus 21 AE 15%; P < 0.05) observation. CRP values did not predict prognosis.
Five-year survival as related to monocyte coculture IL-6 secretion At the 5-year observation, dichotomized (by median) monocyte secretion IL-6 levels following coculture with both malignant and benign spheroids exhibited a strong trend towards predicting survival, that is a low activation predicted a worse prognosis. A low monocyte malignant coculture response gave an observed survival of 31 AE 17 versus 58 AE 17% with a high such response (P = 0.057; Fig. 3 ). Likewise, benign monocyte coculture responses showed a survival of 57 AE 2 versus 32 AE 2% with high versus low IL-6 values (P = 0.061), respectively (Fig. 3) . At 5 years, if both the benign and malignant monocyte cocultures yielded a low response, 15 of 17 patients were deceased compared to 19 out of 43 patients in the other group (P = 0.002; Fig. 4) . Background or direct LPSstimulated monocyte IL-6 secretion did not predict prognosis (results not shown).
When including combined malignant and benign sum score results in a Cox regression survival analysis, together with the age and gender of the patients, the coculture results still predicted survival (HR = 0.42; CI = 0.20-0.86; P < 0.05; Table 3 ). With the additional inclusion of haemoglobin and albumin values to the Cox analysis, the RR ¼ pg/ml coculture secretion -pg/ml background secretion pg/ml LPS-stimulated secretion -pg/ml background secretion . combined monocyte coculture results seemingly predicted prognosis better (HR = 0.32, CI = 0.14-0.73; P < 0.01; Table 3 ).
Ten-year survival and monocyte coculture stimulated IL-6 secretion
At the 10-year observation, 22 of the originally included 65 included patients were still alive. When studying the combined results from both the monocyte benign and malignant cocultures, no new patient with a dual low such value had died between the 5-year observation and 10-year observation. The survival among the other patients was 41 AE 15%, still yielding a significant survival prediction (P < 0.05; Fig. 4 ). When studying survival at this time point by Cox regression survival analysis, including the age, gender and HPV status of patients, survival remained predictive (HR = 0.48, CI = 0.24-0.96; P < 0.05; Table 4 ). If information about haemoglobin and albumin levels at diagnosis was added as well, the monocyte coculture prediction was statistically strengthened (HR = 0.35, CI = 0.16-0.76; P < 0.01; Table 4 ). Background monocyte and LPS-stimulated IL-6 secretion did not predict prognosis (results not shown).
Survival as related to monocyte coculture MCP-1 secretion
The MCP-1 coculture responses or background secretion levels did not predict prognosis.
Survival dependent on monocyte coculture IL-6 secretion as adjusted by HPV status Systematically, the survival Cox regression analyses were adjusted by whether the patients were HPV infected or not without removing the monocyte coculture survival prediction (Table 3-4) . Only one HPV+ patient died during the observation period; thus, it is impossible to conclude about the level of the coculture survival prediction within the HPV-positive group. Fig. 5 shows the Kaplan-Meier plot based on the survival of the HPV-patients following 5 and 10 years. At 5 years, the survival was 12.5 AE 16 versus 47 AE 17% (P < 0.05), while at 10 years, the survival was 12.5 AE 16 versus 29 AE 16% (P = 0.06).
Discussion
We have studied the 5-and 10-year overall survivals of IL-6 and MCP-1 secretion from freshly isolated monocytes stimulated with autologous malignant or benign spheroids 24 h in vitro 2 weeks following surgery, although prior to radiation therapy, in HNSCC patients. IL-6 levels predicted both 5-and 10-year prognoses. It should be noted that the coculture IL-6 response from the spheroids is measurable, but constitutes only a minute fraction of the total determined IL-6 secretion [34] . Furthermore, the monocyte background or LPS-stimulated IL-6 secretion rate at this time point did not predict prognosis, thereby suggesting that monocyte function fundamentally relates to HNSCC biology. Preclinical models strongly suggest that inflammatory chemokines such as MCP-1 play an important role in relation to cancer prognosis through, for example enhancing metastasis formation [35] . We have previously shown a survival prediction from the MCP-1 secretion of LPSstimulated monocytes in HNSCC patients [11] . Despite this, we have not presently tied MCP-1 secretion levels to prognosis. Other coculture conditions may show a survival prediction.
The IL-6 monocyte secretory levels were scored following the relative difference between the LPS pathogen-associated molecular pattern (PAMP) [10] and spheroid-associated response, which consisted of several possible stimuli such as damage-associated molecular pattern (DAMP) [36] and secretory products of the spheroid cells [37] . The current study cannot specifically answer this question, but do support a role of MNPs in the cancer trajectory.
The magnitude of the benign and malignant coculture responses was statistically correlated in the present cohort. Moreover, both the benign and malignant spheroid monocyte coculture IL-6 responses analysed individually demonstrated a trend towards predicting a favourable survival with high such responses. If only patients with a low both benign and malignant coculture monocyte responses were included, the prognosis was significantly worse among these patients compared to the patients with at least one high such response. These results support that it is a monocyte characteristic, or a characteristic common to both benign and malignant spheroids that account for the survival prediction.
The benign spheroids may contain dysplastic epithelial stem cells that represent the origin of the neoplasia [38] . An elevated monocyte production of IL-6 with benign cocultures may be linked to dysplastic-transformed epithelial stimulating monocytes. The spheroids may also carry DAMP material on the surface [36] , which could account for the observed prognostic-relevant IL-6 secretion. Monocytes harvested at diagnosis from HNSCC patients secreted IL-6 levels when stimulated by LPS, which has been shown to predict prognosis [10] . The present utilized monocytes were obtained 2 weeks after surgery and did not predict prognosis when likewise stimulated, but may be primed in vivo.
Levels of blood inflammatory-related components may predict survival in HNSCC patients [39] , as well as affect the monocyte in vitro function. We have currently employed autologous serum during coculture. Therefore, values of albumin, CRP and haemoglobin at diagnosis were collected. When including these parameters to the present Cox survival analyses, the IL-6 survival predictions were mostly strengthened. This argues against that the general inflammatory condition of the patient explains the present prediction of the monocyte IL-6 coculture responses.
We found no significant difference in MCP-1 or IL-6 secretion levels within the cocultures dependent on a tumour's HPV infection status. To some extent, this is opposite to what is observed with the LPS stimulation of monocytes harvested from HNSCC patients at diagnosis [10, 11] . Additionally, survival predictions dependent on IL-6 secretion levels were significant also after correction for HPV infection status. However, the current study included few HPV+ patients and therefore carries a low statistical power. Thus, the prediction from IL-6 secretion to survival for the HPV+ patients cannot be fully addressed. This area of monocyte function should be further studied.
IL-6 has been shown to be associated with prognosis not only in cancer diseases [40] , but also in, for example, atherosclerosis and autoimmune disease [40] . As a result, the shown IL-6 survival prediction may be caused by diseases other than HNSCC. However, the present prediction was primarily generated during the first 5 years after diagnosis. This is the period where the HNSCC disease itself in particular generates mortality [41] . It is therefore reasonable to conclude that the observed prognostic prediction is substantially related to the HNSCC. The present and similar results should further encourage using IL-6 as a clinical analysis in order to better calculate the prognosis of the patients.
Within immune therapy for HNSCC patients, a combined therapy with monoclonal IgG antibodies directed against PD-1 and CTLA-4 seems to be promising [42] . The current finding that patients shown to have monocytes easily activated by tumours have a better prognosis may suggest that an in vivo T cell inhibition targeted against MNP function may be present. Hence, to abolish such an inhibition by anti-PD-1/CTLA-4 may be one mechanism behind the effect of such therapy.
In conclusion, high monocyte IL-6 secretion in cocultures of spheroids derived from HNSCCs with autologous monocytes predicted improved 5-and 10-year overall survivals seemingly independent of HPV infection status. A further disclosure of the interactions between MNPs and cancer cells should contribute to the development of new immunotherapy.
